Ophthalmic Drug Delivery82

Issue No #82 January 22nd, 2018

Inside the magazine

FANNY SELLIER, NEMERA

FANNY SELLIER, NEMERA

Talking here with ONDrugDelivery Magazine, Ms Sellier discusses Nemera’s multidose eyedropper system Novelia® for preservative-free formulations. She explains how this platform has been developed to improve patients’ lives.

AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY

Dr Christian Roesky

AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY

Traditional aqueous vehicles for topical ophthalmic medications suffer from a number of limitations. Christian Roesky reviews the benefits of EyeSol®, a proprietary aqueous-free drug delivery technology.

PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS

PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS

Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.

USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY

USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY

Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.

SUSTAINED RELEASE OCULAR THERAPEUTICS

Michael O'Rourke

SUSTAINED RELEASE OCULAR THERAPEUTICS

Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.

BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY

Re-Vana Therapeutics

BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY

Raj Thakur and Prof David Jones discuss the difficulty of treating diseases of the back and front of the eye, and introduce a possible solution: OcuLief™ and EyeLief™, Re-Vana’s two proprietary sustained-release platforms.

CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE

Dr Patricia Zilliox

CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE

Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.

Top